One of the services that Icarus Consultants offers pharma & biotech companies is help in identifying molecular targets for new products that have both a valid scientific, clinical rationale and viable commercial opportunity.
Sally Church, PhD is our new products specialist and writes the Pharma Strategy Blog. In a recent post, she discusses research that suggests the protein CRKL “may well be a valid therapeutic target” in a subset of patients in non small cell lung cancer (NSCLC).
One of the interesting observations that Sally makes from this research is that:
“CRKL could act as an oncogene in other cancers with CRKL amplifications”
Sally also notes that it would be:
“very interesting to see what happens in the clinic to a subset of lung cancer patients with CRKL amplification who are treated with an EGFR and PI3K inhibitor to see if this reduces resistance to treatment and improves outcomes.”
You can read more about EGFR resistance in lung cancer and possible new molecular targets on Pharma Strategy Blog.
Sally Church will be at the forthcoming AACR-IASCL joint conference on the Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine in San Diego from January 8-11, 2012.